ArticleFrontiers in endocrinology2022

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.

Yuichi Takashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.